Gaps in availability of both meningococcal ACWY and B vaccines exist for high risk groups
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Martin NV, Ong KS, Howden BP, et al. Rise in invasive serogroup W meningococcal disease in Australia 2013–2015. Commun Dis Intell Q Rep 2016; 40: E454–E459.
- 2. Lawrence GL, Wang H, Lahra M, et al. Meningococcal disease epidemiology in Australia 10 years after implementation of a national conjugate meningococcal C immunization programme. Epidemiol Infect 2016; 144: 2382–2391.
- 3. Archer BN, Chiu CK, Jayasinghe SH, et al. Epidemiology of invasive meningococcal B disease in Australia, 1999–2015: priority populations for vaccination. Med J Aust 2017; 207: 382–387. https://www.mja.com.au/journal/2017/207/9/epidemiology-invasive-meningococcal-b-disease-australia-1999-2015-priority
- 4. Australian Government, Department of Health. Invasive meningococcal disease national surveillance quarterly report; quarter 4, 2018. https://www.health.gov.au/internet/main/publishing.nsf/Content/5FEABC4B495BDEC1CA25807D001327FA/$File/1Oct-31Dec19-qrt3-IMD.pdf (viewed June 2019).
- 5. Wang B, Clarke M, Thomas N, et al. The clinical burden and predictors of sequelae following invasive meningococcal disease in Australian children. Pediatr Infect Dis J 2014; 33: 316–318.
- 6. Australian Technical Advisory Group on Immunisation. The Australian immunisation handbook: meningococcal disease. Canberra: Australian Government, Department of Health, 2018. https://immunisationhandbook.health.gov.au/vaccine-preventable-diseases/meningococcal-disease (viewed Jan 2020).
- 7. Figueroa J, Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 1991; 4: 359–395.
- 8. National Centre for Immunisation Research and Surveillance. Significant events in meningococcal vaccination practice in Australia, 2019. http://ncirs.org.au/sites/default/files/2019-12/Meningococcal-history-Dec%202019.pdf (viewed Jan 2020).
- 9. Marshall H, McMillan M, Koehler A, et al. Meningococcal B vaccine and meningococcal carriage in adolescents in Australia. N Engl J Med 2020; 382: 318–327.
- 10. Christensen H, May M, Bowen L, et al. Meningococcal carriage by age: a systematic review and meta‐analysis. Lancet Infect Dis 2010; 10: 853–861.
- 11. Northern Territory Government, Department of Health. Update — meningococcal outbreak in Central Australia, 2017. http://mediareleases.nt.gov.au/mediaRelease/23779 (viewed July 2019).
- 12. Wang B, Santoreneos R, Giles L, et al. Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta‐analysis. Vaccine 2019; 37: 2768–2782.
- 13. Nolan T, Santolaya ME, de Looze F, et al. Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine. Vaccine 2019; 37: 1209–1218.
- 14. Ladhani S, Andrews N, Parikh S, et al. Vaccination of infants with meningococcal group B vaccine (4CMenB) in England. N Engl J Med 2020; 382: 309–317.
- 15. Medini D, Stella M, Wassil J. MATS: global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine. Vaccine 2015; 33: 2629–2636.
- 16. Nolan TM. The Australian model of immunization advice and vaccine funding. Vaccine 2010; 28: A76–A83.
- 17. Trotter C, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines 2009; 8: 851–861.
- 18. Pharmaceutical Benefits Advisory Committee. May 2019 PBAC meeting — positive recommendations. http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/2019-05/positive-recommendations-05-2019.pdf (viewed June 2019).
- 19. Pharmaceutical Benefits Advisory Committee. Public summary document — 5.06 meningococcal polysaccharide conjugate vaccine serogroups A, C, W‐135 and Y, pre‐filled syringe, 0.5 mL, Nimenrix, Pfizer Australia Pty Ltd. 2018. http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2018-03/files/men-acwy-vaccine-infants-psd-march-2018.pdf (viewed July 2019).
- 20. Pharmaceutical Benefits Advisory Committee. November 2019 PBAC meeting — positive recommendations. http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/2019-11/positive-recommendations-11-2019.docx.pdf (viewed Jan 2020).
- 21. Beard FH, Clark KK. High rates of vaccination of Aboriginal and Torres Strait Islander Australians: an underappreciated success? Med J Aust 2019; 211: 17–18. https://www.mja.com.au/journal/2019/211/1/high-rates-vaccination-aboriginal-and-torres-strait-islander-australians
Online responses are no longer available. Please refer to our instructions for authors page for more information.
We thank Katrina Clark for her review and input into the article. The authors received no financial support specifically for the authorship and/or publication of this article. The views expressed in this article are those of the individual authors, and are not necessarily the views of the Australian Technical Advisory Group on Immunisation (ATAGI), the Department of Health, or the National Immunisation Program. For information from the ATAGI, please see the meningococcal chapter in the Australian immunisation handbook.
Cyra Patel, Clayton Chiu, Frank Beard and Kristine Macartney are employed at the National Centre for Immunisation Research and Surveillance, which receives funding from the Australian Government Department of Health for contracted work to support ATAGI. No specific funding was provided for the drafting or publication of this manuscript.